Literature DB >> 1863547

Mass screening for neuroblastoma in Japan.

T Sawada1, T Sugimoto, H Kawakatsu, T Matsumura, Y Matsuda.   

Abstract

The present status of the neuroblastoma mass screening program in Japan, the first national trial in the world, is evaluated. This program, now in its fifth year, was conducted in cooperation with the infants' mothers, local health centers, screening centers, and selected hospitals. From the onset of the program in Kyoto in 1973 to the end of 1989, 337 cases were detected and analyzed. Most cases were detected at early stages and 97% are expected to be cured. Several social, technical, and clinical problems remain unresolved.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1863547     DOI: 10.3109/08880019109033437

Source DB:  PubMed          Journal:  Pediatr Hematol Oncol        ISSN: 0888-0018            Impact factor:   1.969


  5 in total

Review 1.  Screening for neuroblastoma.

Authors:  S N Huddart; J R Mann
Journal:  Arch Dis Child       Date:  1991-11       Impact factor: 3.791

Review 2.  Mechanisms of neuroblastoma regression.

Authors:  Garrett M Brodeur; Rochelle Bagatell
Journal:  Nat Rev Clin Oncol       Date:  2014-10-21       Impact factor: 66.675

3.  The physician's hands and early detection of neuroblastoma.

Authors:  J Armata; M Hnatko-Kolacz
Journal:  Arch Dis Child       Date:  1994-03       Impact factor: 3.791

4.  Diagnosis and subsequent US-guided percutaneous drainage of an adrenal abscess in a 5-week-old infant.

Authors:  S C E Diepstraten; S Zwaveling; F J A Beek
Journal:  Pediatr Radiol       Date:  2012-04-18

Review 5.  Is neuroblastoma screening evaluation needed and feasible?

Authors:  J Estève; L Parker; P Roy; F Herrmann; S Duffy; D Frappaz; C Lasset; C Hill; H Sancho-Garnier; J Michaelis
Journal:  Br J Cancer       Date:  1995-06       Impact factor: 7.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.